Next Article in Journal
Plant MicroRNAs in Cross-Kingdom Regulation of Gene Expression
Next Article in Special Issue
Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach
Previous Article in Journal
DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells
Previous Article in Special Issue
GPCRs in Cancer: Protease-Activated Receptors, Endocytic Adaptors and Signaling
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(7), 2006; https://doi.org/10.3390/ijms19072006

Application of Nanoparticles for Targeting G Protein-Coupled Receptors

Centre of Reproduction Development and Aging, Faculty of Health Sciences, University of Macau, Taipa, Macau, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 30 May 2018 / Revised: 28 June 2018 / Accepted: 4 July 2018 / Published: 10 July 2018
(This article belongs to the Special Issue Cancer-Driver G Protein-Coupled Receptors as Therapeutic Targets)
Full-Text   |   PDF [1056 KB, uploaded 10 July 2018]   |  

Abstract

Nanoparticles (NPs) have attracted unequivocal attention in recent years due to their potential applications in therapeutics, bio-imaging and material sciences. For drug delivery, NP-based carrier systems offer several advantages over conventional methods. When conjugated with ligands and drugs (or other therapeutic molecules), administrated NPs are able to deliver cargo to targeted sites through ligand-receptor recognition. Such targeted delivery is especially important in cancer therapy. Through this targeted cancer nanotherapy, cancer cells are killed with higher specificity, while the healthy cells are spared. Furthermore, NP drug delivery leads to improved drug load, enhanced drug solubility and stability, and controlled drug release. G protein-coupled receptors (GPCRs) are a superfamily of cell transmembrane receptors. They regulate a plethora of physiological processes through ligand-receptor-binding-induced signaling transduction. With recent evidence unveiling their roles in cancer, GPCR agonists and antagonists have quickly become new targets in cancer therapy. This review focuses on the application of some notable nanomaterials, such as dendrimers, quantum dots, gold nanoparticles, and magnetic nanoparticles, in GPCR-related cancers. View Full-Text
Keywords: G protein-coupled receptor (GPCR); cancer; nanoparticles (NPs); dendrimers; quantum dots (QDs); gold nanoparticles (AuNPs); magnetic nanoparticles (MNPs) G protein-coupled receptor (GPCR); cancer; nanoparticles (NPs); dendrimers; quantum dots (QDs); gold nanoparticles (AuNPs); magnetic nanoparticles (MNPs)
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Ma, X.; Xiong, Y.; Lee, L.T.O. Application of Nanoparticles for Targeting G Protein-Coupled Receptors. Int. J. Mol. Sci. 2018, 19, 2006.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top